Pharming Specifies its 2026 Financial Goals and Progress of Clinical Programs
Pharming Group N.V. unveiled on Tuesday its financial outlook for 2026 during an investor day, announcing expected revenues between $405 and $425 million for the year. The biopharmaceutical group based in Leiden, Netherlands, highlighted two major programs from its clinical portfolio currently under development: leniolisib for primary immunodeficiencies with immune dysregulation and napazimone for mitochondrial diseases.
Financial Projections for 2026
Pharming Group anticipates total revenues ranging from $405 to $425 million for the fiscal year 2026, driven by its commercial products. According to Fabrice Chouraqui, CEO of Pharming, the company's vision to become a major global player in the rare disease sector is supported by the strength of its two commercial products and its high-value research portfolio. The group expects its commercial portfolio to continue generating robust growth. The announcement detailed that leniolisib is currently approved and marketed in the United States under the name Joenja as the first and only targeted therapy for APDS (activated phosphoinositide 3-kinase delta syndrome), a rare and progressive primary immunodeficiency, intended for patients aged 12 and older. Leniolisib is an oral selective inhibitor of phosphoinositide 3-kinase delta and has also received approvals or marketing authorizations in other countries.
Major Clinical Programs Under Development
Pharming is developing two major programs in clinical phase. Leniolisib is currently being evaluated in two phase II proof-of-concept clinical trials: one in patients with genetically defined primary immunodeficiencies related to PI3K signaling, and the other in patients with common variable immunodeficiency with immune dysregulation. Intermediate data from these two trials are expected in the second half of 2026. Napazimone, recently named, is being developed for mitochondrial diseases related to mitochondrial DNA mutations and could become the first standard of treatment in this indication if approved. The ongoing pivotal FALCON clinical trial is expected to produce its results in 2027. Napazimone targets adult patients with primary mitochondrial disease caused by mitochondrial DNA mutations, a rare and debilitating condition characterized by altered energy production, significant fatigue, and muscle weakness with reduced life expectancy.
Investor Day Event Details
The investor day took place on Tuesday, February 3, 2026, from 10:00 AM to 12:00 PM EST, which is 4:00 PM to 6:00 PM CET, in a virtual format. The event presented in-depth scientific and clinical perspectives on the biological rationale, clinical strategy, and long-term opportunities of these research programs. Pharming Group N.V. is listed on Euronext Amsterdam under the ticker PHARM and on Nasdaq under the ticker PHAR. The company is based in Leiden, Netherlands, with a significant part of its workforce located in the United States.
